Petition request

That the House of Representatives urge the Government to provide funding to Pharmac for the medication Pemigatinib (Pemazyre).

Petition reason

Pemigatinib (Pemazyre) treats adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. Currently it costs $7,200 per month. It is approved in the United States and Japan.

Related

Download Final Select Committee Report Go to page

Petition progress

  • Open for signatures
  • Closed for signatures
  • Select Committee
  • Reported
  • Referred to Minister
Number of signatures: 658
Date presented: 09 Apr 2024
Considered by: Health
SC Report(s): 26 Sep 2024 (Final)
Presenting member: Cameron, Mark
Closing date: 19 Feb 2024